OBR Daily Commentary

forumImage

Dana-Farber Cancer Institute Analyzes Clinical Pathway Use to Reduce Unwarranted Variation

(Journal of Clinical Pathways) Sept 27 2018 - Researchers at the Dana-Farber Cancer Institute (Boston, MA) analyzed off-pathway cases to reduce unwarranted variation, understand practice patterns, and update their clinical pathways.

Read Article arrow

Winston Wong, PharmD (Posted: October 15, 2018)

quotesThis piece is a great example of a pathway program in process. Clinical pathways are not meant to be static. Their goal is to decrease variability and improve quality, however through the learning process, must be updated based upon experience and new learning. Hence every good pathway program must be reviewed and update periodically.quotes

Add Comment 1 Comment
forumImage

With New Blood Test, Roche Dives Deeper Into Personal Cancer Care

(Reuters) Sept 24, 2018 - Swiss drugmaker Roche upped its bet on personalized cancer treatment on Monday, saying it is now ready to sell a blood test around the world that can identify common gene mutations from solid tumors from a patient’s blood. The blood test, called FoundationOne Liquid, is among initial products to emerge from Foundation Medicine after Roche spent $2.4 billion on the U.S.-based genetic profiling company this year on the conviction that future cancer treatment will be tailored to individual characteristics of a patient’s tumor. Foundation’s new blood test can identify circulating tumor DNA as 70 of the most commonly mutated genes in solid tumors, Roche said, including features which may help identify patients most likely to benefit from cancer immunotherapy.

Read Article arrow

Winston Wong, PharmD (Posted: October 15, 2018)

quotesFrom a payer perspective, I do not think the clinical utility of the liquid biopsy has been show to warrant wide spread coverage. While I am a proponent of the liquid biopsy, I do not think it has gain "prime time" status. It has shown utility in only a few solid tumors, those of which are know to be active cell shedders. It will be interesting to see if payers will pick up coverage of the test.quotes

Add Comment 1 Comment
forumImage

Senate Passes Bill To Ban ‘Gag Clauses’ And Free Pharmacists To Discuss Drug Pricing Options

(STAT) Sept 17, 2018 - The Senate on Monday overwhelmingly passed a bill that would let pharmacists inform consumers when it’s cheaper to buy a drug without insurance, as lawmakers inched closer to delivering the Trump administration a win — albeit a small one — in the effort to lower drug prices.

Read Article arrow

Winston Wong, PharmD (Posted: October 15, 2018)

quotesI have to wonder who the 2 negative votes are, and why did they oppose the bill. I also wonder how deep this regulation will go. If States have already passed similar bills, and the practice is still prevalent, there must be a loophole. Is that Loop hole in the contracting between the pharmacies and the network administrators, or by pharmacy corporate headquarters due to volume purchase agreements? I think there has to be more here than just passing a regulation to open up the lower price gates.quotes

Add Comment 1 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...